Imaging genomics is a rapidly evolving field that combines state-of-the-art bioimaging with genomic information to resolve phenotypic heterogeneity associated with genomic variation, improve risk prediction, discover prevention approaches, and enable precision diagnosis and treatment. Contemporary bioimaging methods provide exceptional resolution generating discrete and quantitative high-dimensional phenotypes for genomics investigation. Despite substantial progress in combining high-dimensional bioimaging and genomic data, methods for imaging genomics are evolving. Recognizing the potential impact of imaging genomics on the study of heart and lung disease, the National Heart, Lung, and Blood Institute convened a workshop to review cutting-edge approaches and methodologies in imaging genomics studies, and to establish research priorities for future investigation. This report summarizes the presentations and discussions at the workshop. In particular, we highlight the need for increased availability of imaging genomics data in diverse populations, dedicated focus on less common conditions, and centralization of efforts around specific disease areas.
|Journal||Circulation: Cardiovascular Imaging|
|State||Published - Aug 1 2021|
Bibliographical noteFunding Information:
Dr Nayor acknowledges support from grant K23-HL138260 from the National Heart, Lung, and Blood Institute (NHLBI). Dr Shen acknowledges support from National Institutes of Health (NIH) grants R01 EB022574, R01 LM013463, and U01 AG068057 and NSF grant IIS1837964. Dr Hunninghake acknowledges support from NHLBI and NIH with grants R01 HL 111024, R01 HL135142, and R01 HL130974. Dr Kochunov acknowledges support from NIH grants R01 EB015611, P50 MH103222, R01 NS114628, and U01 MH108148. Dr Barr acknowledges support from NHLBI with grants R01 HL077612, R01 HL093081, R01 HL121270 and R01 HL1422028. Dr Broeckel acknowledges support from NHLBI through the grants 1R01HL125580, 1R01HL140493, and 1R01HL107577. Dr Caravan acknowledges support from the NHLBI with grants R01 HL109448, R01 HL116315, R01 HL131907, R33 HL154125, and R01 HL153606. Dr Cheng acknowledges support from the NHLBI with grants R01 HL134168, R01 HL131532, R01 HL143227, R01 HL142983. Dr de Vries was supported by NHLBI grants R01HL146860 and American Heart Association grant 18CDA34110116. Dr McNally was supported by NIH U01 HG011169, NIH U01 HL131914, NIH R01 HL128075 and the American Heart Association SFRN on Arrhythmias and Sudden Cardiac Death. Dr Arnett acknowledges support from NHLBI with grants R01 HL55673. Dr Thanassoulis is supported by the Canadian Institutes of Health Research, the Fonds de Recherche Qué-bec-Santé, and by NHLBI grant R01 HL128550. Dr Vasan acknowledges support from the Framingham Heart Study (FHS) Contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from NHLBI and by NIH grants HL107385, HL126136, HL93328, HL 142983, HL143227 and HL 131532, U01HL146382, R01HL146860, and R01HL128550. He is supported also in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.
Dr McNally consults for Amgen, AstraZeneca, Avidity, 4D Molecular Therapeutics, Cytokinetics, Janssen, Pfizer, Tenaya, Invitae Corp and Exonics. She is the founder of Ikaika Therapeutics. These activities are unrelated to the content of this article. Dr Thanassoulis has participated in advisory boards and speaker bureaus for Amgen, Regeneron/Sanofi, HLS therapeutics, Novartis, and Silence therapeutics. Dr Barr receives grant funding from the COPD Foundation outside the submitted work.
© 2021 Lippincott Williams and Wilkins. All rights reserved.
- cardiovascular disease
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine